Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression.

Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, Egranov SD, Zhang Y, Xia W, Gong J, Pan Y, Chatterjee SS, Yao J, Evans KW, Nguyen TK, Park PK, Liu J, Coarfa C, Donepudi SR, Putluri V, Putluri N, Sreekumar A, Ambati CR, Hawke DH, Marks JR, Gunaratne PH, Caudle AS, Sahin AA, Hortobagyi GN, Meric-Bernstam F, Chen L, Yu D, Hung MC, Curran MA, Han L, Lin C, Yang L.

Nat Immunol. 2019 Jul;20(7):835-851. doi: 10.1038/s41590-019-0400-7. Epub 2019 Jun 3.

PMID:
31160797
2.

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.

Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, Selby MJ, Graziano RF, Mardis ER, Korman AJ, Schreiber RD.

Cancer Immunol Res. 2017 Feb;5(2):106-117. doi: 10.1158/2326-6066.CIR-16-0391. Epub 2017 Jan 10.

3.

Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.

Bamodu OA, Huang WC, Lee WH, Wu A, Wang LS, Hsiao M, Yeh CT, Chao TY.

BMC Cancer. 2016 Feb 25;16:160. doi: 10.1186/s12885-016-2108-5.

4.

p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.

Powell E, Shao J, Yuan Y, Chen HC, Cai S, Echeverria GV, Mistry N, Decker KF, Schlosberg C, Do KA, Edwards JR, Liang H, Piwnica-Worms D, Piwnica-Worms H.

Breast Cancer Res. 2016 Jan 27;18(1):13. doi: 10.1186/s13058-016-0673-9.

5.

Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.

Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z, Fu Y, Huang M, Vlad AM, Lu B, Oesterreich S, Davidson NE, Huang Y.

Oncogene. 2019 Jan;38(3):390-405. doi: 10.1038/s41388-018-0451-5. Epub 2018 Aug 15.

6.

The Potential Roles of Long Noncoding RNAs (lncRNA) in Glioblastoma Development.

Liu S, Mitra R, Zhao MM, Fan W, Eischen CM, Yin F, Zhao Z.

Mol Cancer Ther. 2016 Dec;15(12):2977-2986. doi: 10.1158/1535-7163.MCT-16-0320. Epub 2016 Oct 26.

7.

RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.

Knudsen ES, McClendon AK, Franco J, Ertel A, Fortina P, Witkiewicz AK.

Cell Cycle. 2015;14(1):109-22. doi: 10.4161/15384101.2014.967118.

8.

Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPδ expression and contributes to transformation of breast tumor cells.

Sarkar TR, Sharan S, Wang J, Pawar SA, Cantwell CA, Johnson PF, Morrison DK, Wang JM, Sterneck E.

Mol Cell Biol. 2012 Jan;32(2):320-32. doi: 10.1128/MCB.05790-11. Epub 2011 Oct 28.

9.

Long Noncoding RNA PVT1 Promotes Non-Small Cell Lung Cancer Cell Proliferation through Epigenetically Regulating LATS2 Expression.

Wan L, Sun M, Liu GJ, Wei CC, Zhang EB, Kong R, Xu TP, Huang MD, Wang ZX.

Mol Cancer Ther. 2016 May;15(5):1082-94. doi: 10.1158/1535-7163.MCT-15-0707. Epub 2016 Feb 23.

10.

c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.

Morrison CD, Allington TM, Thompson CL, Gilmore HL, Chang JC, Keri RA, Schiemann WP.

Oncotarget. 2016 Nov 8;7(45):72777-72794. doi: 10.18632/oncotarget.11909.

11.

LncRNA CamK-A Regulates Ca2+-Signaling-Mediated Tumor Microenvironment Remodeling.

Sang LJ, Ju HQ, Liu GP, Tian T, Ma GL, Lu YX, Liu ZX, Pan RL, Li RH, Piao HL, Marks JR, Yang LJ, Yan Q, Wang W, Shao J, Zhou Y, Zhou T, Lin A.

Mol Cell. 2018 Oct 4;72(1):71-83.e7. doi: 10.1016/j.molcel.2018.08.014. Epub 2018 Sep 13. Erratum in: Mol Cell. 2018 Nov 1;72(3):601.

PMID:
30220561
12.

Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.

Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, Tan Y, Ci Y, Wu F, Dai X, Guo J, Huang YH, Fan C, Ren S, Sun Y, Freeman GJ, Sicinski P, Wei W.

Nature. 2018 Jan 4;553(7686):91-95. doi: 10.1038/nature25015. Epub 2017 Nov 16. Erratum in: Nature. 2019 Jul 3;:.

13.

LncRNA MT1JP functions as a tumor suppressor by interacting with TIAR to modulate the p53 pathway.

Liu L, Yue H, Liu Q, Yuan J, Li J, Wei G, Chen X, Lu Y, Guo M, Luo J, Chen R.

Oncotarget. 2016 Mar 29;7(13):15787-800. doi: 10.18632/oncotarget.7487.

14.

Epigenetics and immunotherapy: The current state of play.

Dunn J, Rao S.

Mol Immunol. 2017 Jul;87:227-239. doi: 10.1016/j.molimm.2017.04.012. Epub 2017 May 14. Review.

15.

HOTTIP: a critical oncogenic long non-coding RNA in human cancers.

Lian Y, Cai Z, Gong H, Xue S, Wu D, Wang K.

Mol Biosyst. 2016 Oct 18;12(11):3247-3253. Review.

PMID:
27546609
16.
17.

Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells.

Palaniappan M, Edwards D, Creighton CJ, Medina D, Conneely OM.

PLoS One. 2018 Mar 28;13(3):e0194913. doi: 10.1371/journal.pone.0194913. eCollection 2018.

18.

Crucial and novel cancer drivers in a mouse model of triple-negative breast cancer.

Johnson JP, Kumar P, Koulnis M, Patel M, Simin K.

Cancer Genomics Proteomics. 2014 May-Jun;11(3):115-26.

PMID:
24969692
19.

Ubiquinol-cytochrome C reductase core protein II promotes tumorigenesis by facilitating p53 degradation.

Han Y, Wu P, Wang Z, Zhang Z, Sun S, Liu J, Gong S, Gao P, Iwakuma T, Molina-Vila MA, Chen BP, Zhang Y, Ji T, Mo Q, Chen P, Hu J, Wang S, Zhou J, Lu H, Gao Q.

EBioMedicine. 2019 Feb;40:92-105. doi: 10.1016/j.ebiom.2019.01.002. Epub 2019 Jan 20.

20.

MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.

Maeda T, Hiraki M, Jin C, Rajabi H, Tagde A, Alam M, Bouillez A, Hu X, Suzuki Y, Miyo M, Hata T, Hinohara K, Kufe D.

Cancer Res. 2018 Jan 1;78(1):205-215. doi: 10.1158/0008-5472.CAN-17-1636. Epub 2017 Dec 20.

Supplemental Content

Support Center